ライフサイエンスコーパス: MRA

1 MRA blocked all the above effects.

2 MRA escape leads to false-negative genetic interaction r

3 MRA for screening followed by carbon dioxide angiography

4 MRA index, % wall volume, and ankle-brachial index corre

5 MRA treatment appears to be a promising option to reduce

6 MRA was also used to evaluate patient 15 but was unsucce

7 MRAs reduce the risk of SCD in patients with left ventri

8 in the ACR 20% response between the other 3 MRA cohorts and placebo at week 2.

9 ry disease (CAD) underwent free-breathing 3D MRA with and without T2prep and with 120- and 60-ms data

10 suspected venous anomalies were imaged by 3D MRA.

11 ed all patients who underwent Gd-enhanced 3D MRA examination from January 1998 through January 2001,

12 Gadolinium-enhanced 3D MRA is a fast and accurate technique for delineation of

13 Gadolinium-enhanced 3D MRA is a fast magnetic resonance imaging technique that

14 Gadolinium-enhanced 3D MRA is capable of rapidly and accurately diagnosing a wi

15 In 74% of patients, 3D MRA either diagnosed previously unsuspected venous anoma

16 The 3D MRA diagnoses were followed by 10 interventional cathete

17 r CAI; sensitivities were 53% (CTA) and 47% (MRA) for VAI.

18 Furthermore, patients with abnormal MRA findings and higher TCD velocities are at higher ris

19 ard care arm, 4 of 13 patients with abnormal MRA findings had strokes compared with 5 of 40 patients

20 erated by nordexfenfluramine administration, MRA treatment reduced mitral valve thickness and proteog

21 In the 7 days after MRA initiation among patients who remained alive and out

22 se are at high risk for adverse events after MRA initiation.

23 ction is common, laboratory monitoring after MRA initiation frequently does not meet guideline recomm

24 nd creatinine (Cr) before and serially after MRA initiation, but the extent to which this occurs is u

25 -alpha treatment, the promising alternatives MRA, abatacept, and rituximab have been tested.

26 Although MRA has been shown to be more cost effective and to have

27 Initial ambulatory MRA dispensing occurred at hospital discharge in 70.0% o

28 Among MRA-treated patients with symptomatic HFrEF, severe hype

29 An MRA temporal-superior sector outside normal limits had a

30 Ucn2 and an MRA (canrenoic acid [CA]) were infused for 4 hours, both

31 ally having healthy neuroretinal rims and an MRA analysis of within normal limits in all sectors.

32 tions of acute administration of Ucn2 and an MRA in experimental HF.

33 with short-term adjunct Ucn2 therapy and an MRA in HF.

34 iabetes) despite the above treatments and an MRA.

35 neficiaries with heart failure started on an MRA, 19.7% were initiated during a hospitalization.

36 We randomized 1,603 patients to receive an MRA regimen with a single intravenous bolus of potassium

37 d participants [21.6% female]) not taking an MRA at baseline, the 4671 patients (55.6% [22.0% female]

38 Among those taking an MRA at baseline, the overall rates of hyperkalemia were

39 71 patients (55.6% [22.0% female]) taking an MRA tended to be younger, with a lower EF, lower systoli

40 mong patients treated or not treated with an MRA at baseline and the risk of subsequent hyperkalemia

41 hyperkalemia for those newly treated with an MRA during study follow-up were defined in time-updated

42 Ucn2 cotreatment with an MRA in HF further improved hemodynamics relative to that

43 Treatment with an MRA reduced pericellular fibrosis, synthesis of the majo

44 calin-like prostaglandin D2 synthase with an MRA.

45 xture of desiccated Martian Regolith Analog (MRA) substrate, salts, and microbial cells, which over t

46 GPS) and the Moorfields Regression Analysis (MRA) for discriminating between glaucomatous and healthy

47 The overall Moorfields regression analysis (MRA) result from the HRT was used as a separate diagnost

48 nd HRT-based Moorfields Regression Analysis (MRA) results of outside normal limits in any sector.

49 Moorfields Regression Analysis (MRA) with CLST was performed globally and sectorally to

50 PS), the HRT Moorfields regression analysis (MRA), scanning laser polarimetry (GDx enhanced corneal c

51 ork inference and master regulator analysis (MRA) have been widely adopted to define specific transcr

52 ion of MRA is less than histologic analysis, MRA-obtained vascular attributes provide useful informat

53 EGFR phosphorylation in coronary artery and MRA dysfunction in diabetic db/db mice.

54 ice with AG1478 improved coronary artery and MRA endothelial function and restored eNOS expression.

55 et doses of ACEI/ARB/ARNI, beta-blocker, and MRA.

56 Cohort B: 9 patients had BOLD and MRA data.

57 Overall reported sensitivity for CTA and MRA (TCD is poorer) was 76-98% and specificity was 85-10

58 CTA and MRA are much poorer methods for the detection of aneurys

59 Although CTA and MRA can detect some proximal moderate to severe arterial

60 Follow-up CTA and MRA were assessed for persistent arterial occlusion or r

61 Comparison of CTA and MRA with cerebral angiography in 143 patients demonstrat

62 less-invasive diagnostic techniques (CTA and MRA) are inadequate for screening.

63 lts suggest that in this population, GPS and MRA differentiate between glaucomatous and healthy eyes

64 Likelihood ratios for regional GPS and MRA results outside normal limits ranged from 4.0 to 10.

65 e on the diagnostic accuracy of both GPS and MRA was evaluated using the generalized estimating equat

66 mproved diagnostic accuracy for both GPS and MRA.

67 ociated with the sensitivity of both GPS and MRA.

68 y and safety of combined SGLT2 inhibitor and MRA treatment.

69 oposed framework was validated using MAP and MRA data collected from 15 patients over a 700-days peri

70 Combining 3D MRI and MRA is effective for quantitatively characterizing CTEV

71 nance brain imaging and angiography (MRI and MRA) at exit showed no new cerebral infarcts in either t

72 angle above the reference plane for MRW and MRA, BMO area, MCD, mean ALCSD, PLTT, RNFLT and visual f

73 OP, 232 brain magnetic resonance angiograms (MRAs) were performed on 100 patients, 47 in the transfus

74 ical CT angiography (CTA) or MR angiography (MRA) for live renal donor evaluation is still controvers

75 ing coronary magnetic resonance angiography (MRA) allows for submillimeter image resolution but suffe

76 ance imaging/magnetic resonance angiography (MRA) and transcranial Doppler (TCD) exams were performed

77 are coronary magnetic resonance angiography (MRA) and x-ray coronary angiography findings in patients

78 ng (MRI) and Magnetic Resonance Angiography (MRA) brain showed a left dorsal tegmental infarct at the

79 -enhanced 3D magnetic resonance angiography (MRA) can provide a noninvasive alternative to diagnostic

80 anges) using magnetic resonance angiography (MRA) data.

81 Magnetic resonance angiography (MRA) demonstrated tight stenoses in the common iliac art

82 rs, that had magnetic resonance angiography (MRA) during the period 2016-2018.

83 Based on MRI/magnetic resonance angiography (MRA) findings, infarct size, and location, 36 patients w

84 of coronary magnetic resonance angiography (MRA) for assessing human epicardial coronary artery vaso

85 re recently, magnetic resonance angiography (MRA) has been compared with conventional angiography.

86 ghted and 3D magnetic resonance angiography (MRA) images were acquired.

87 culopathy by magnetic resonance angiography (MRA) in children with hemoglobin SS, the most serious fo

88 nsional (3D) magnetic resonance angiography (MRA) in patients with congenital and acquired anomalies

89 the value of magnetic resonance angiography (MRA) in the follow-up of patients with autosomal dominan

90 Magnetic resonance angiography (MRA) offers a noninvasive, complementary approach that p

91 ng (MRI) and magnetic resonance angiography (MRA) studies, a neurologic examination by a pediatric ne

92 ng (MRI) and magnetic resonance angiography (MRA) within 6 months of initial imaging.

93 raphy (CTA), magnetic resonance angiography (MRA), and cases of TVAI mimics.

94 tomography, magnetic resonance angiography (MRA), and noncontrast MRA are each of limited use becaus

95 ests such as magnetic resonance angiography (MRA), computed tomographic angiography (CTA) and transcr

96 and cervical magnetic resonance angiography (MRA), could also be risk factors for SCI.

97 ing coronary magnetic resonance angiography (MRA), coverage of the coronary artery tree may be limite

98 MRI, magnetic resonance angiography (MRA), Doppler ultrasound, CT, and positron emission tomo

99 onal flow on magnetic resonance angiography (MRA), quantitative MRA, and high-resolution MRI of the a

100 ts underwent magnetic resonance angiography (MRA), treadmill testing with maximal oxygen consumption

101 -dimensional magnetic resonance angiography (MRA).

102 brosis, and the effects of an MR antagonist (MRA) in human adipocytes remains very limited.

103 ing a mineralocorticoid receptor antagonist (MRA) and with longitudinal systolic BP.

104 While need for receptor antagonist (MRA) MRA after diagnosis suggests that a defined daily d

105 , and mineralocorticoid receptor antagonist (MRA) were examined at baseline and at 12-month follow-up

106 arent mineralocorticoid receptor antagonist (MRA)-resistant' hypertension was defined as systolic blo

107 ith a mineralocorticoid receptor antagonist (MRA).

108 reatments such as interleukin-6 antagonists (MRA), CTLA4Ig (abatacept), and anti-B cell therapy (ritu

109 Mineralocorticoid receptor antagonists (MRA) improve outcome in the setting of post-myocardial i

110 Mineralocorticoid receptor antagonists (MRA) reduce morbidity and mortality in heart failure wit

111 i+BB+mineralocorticoid receptor antagonists (MRA)+SGLT2i (MD, +7.1 [-1.0 to +15.2]), ACE inhibitor+BB

112 BB), mineralocorticoid receptor antagonists (MRA), and angiotensin receptor-neprilysin inhibitors (AR

113 e of mineralocorticoid receptor antagonists (MRAs) for selected patients with symptomatic heart failu

114 Mineralocorticoid receptor antagonists (MRAs) have become established therapy in heart failure (

115 Mineralocorticoid receptor antagonists (MRAs) may attenuate this risk.

116 The mineralocorticoid receptor antagonists (MRAs) spironolactone and eplerenone have proved valuable

117 MR (mineralocorticoid receptor) antagonists (MRAs) improve cardiac function by decreasing cardiac fib

118 ses (mineralocorticoid receptor antagonists [MRAs], angiotensin receptor-neprilysin inhibitors [ARNIs

119 kinra), antiinterleukin-6 receptor antibody (MRA), and rituximab (anti-CD20 monoclonal antibody) are

120 change in OCT parameters (minimum rim area (MRA), minimum rim width (MRW), Bruch's membrane opening

121 y used mouse mesenteric resistance arteries (MRAs) to investigate the role of EGFR transactivation un

122 ary artery and mesenteric resistance artery (MRA) were mounted in an arteriograph.

123 Direct magnetic resonance arthrography (MRA) offers increased diagnostic accuracy compared to co

124 ated non-invasive imaging modalities such as MRA (Magnetic Resonance Angiography) and renal angiograp

125 a congener-specific mixture risk assessment (MRA) of human exposure to combinations of BDE-209 and ot

126 lection is mating-type-regulated auxotrophy (MRA), by which prototrophy is restricted to a particular

127 Baseline MRA findings were interpreted as normal in 75 patients a

128 ents with normal or mildly abnormal baseline MRA but remained abnormal in 8 of 10 patients with sever

129 10 patients with severely abnormal baseline MRA.

130 is suggested that the combination of ACEI+BB+MRA was associated with a 56% reduction in mortality ver

131 The combination of ARNI+BB+MRA resulted in the greatest mortality reduction.

132 4, 95% credible interval 0.26-0.66); ARNI+BB+MRA was associated with the greatest reduction in all-ca

133 A composite of ARNi+BB+SGLT2i or ARNi+BB+MRA+SGLT2i was the most effective at improving quality o

134 +5.3 [-2.6, to +13.3]), and ACE inhibitor+BB+MRA+ivabradine (MD, +5.2 [-3.1 to +13.6]), which were no

135 (MD, +7.1 [-1.0 to +15.2]), ACE inhibitor+BB+MRA+SGLT2i (MD, +5.3 [-2.6, to +13.3]), and ACE inhibito

136 is showed that treatment with ACEI, ARB, BB, MRA, and ARNI and their combinations were better than th

137 In the 30 days before MRA initiation, 94.3% of patients had a K or Cr measurem

138 Although laboratory monitoring before MRA initiation for heart failure with reduced ejection f

139 normalities indicative of stroke risk before MRA lesions become evident.

140 Outcomes included laboratory testing before MRA initiation and in the early (days 1-10) and extended

141 There was complete agreement between MRA and x-ray angiography in the detection of CAA (n=11)

142 The mean difference between MRA and catheterization measurements of 33 pulmonary ves

143 he combination use of an ARNI, beta blocker, MRA, and SGLT2 inhibitor as a new therapeutic standard.

144 pharmacological therapy (ARNI, beta blocker, MRA, and SGLT2 inhibitor) versus conventional therapy (A

145 m width (BMO-MRW); and minimum rim area (BMO-MRA) optimized within sectors and then summed.

146 tor-wise optimized BMO-minimum rim area (BMO-MRA).

147 to differentiate glaucoma was 0.873 for BMO-MRA, compared to 0.866 for BMO-gMRA (P = 0.004).

148 Global and temporal inferior BMO-MRA performed best in differentiating glaucoma patients.

149 jacency constraint within calculation of BMO-MRA does not improve diagnostic power.

150 MD was better correlated with BMO-MRA (r = 0.534) or BMO-MRW (r = 0.546) than with either

151 NFL thickness was better correlated with BMO-MRA (r = 0.676) or BMO-MRW (r = 0.680) than with either

152 , range: 1 day to 46.9 years) underwent both MRA and cardiac catheterization (median time: 1 month).

153 by both modalities, and patients abnormal by MRA often were abnormal by MRI (p < 0.00001).

154 tomatic concurrent aneurysm were detected by MRA in this study in 18 patients from 15 families.

155 pression in eight patients was determined by MRA but not by other imaging modalities.

156 vasculature properties can be determined by MRA.

157 Three additional APCs were diagnosed by MRA but not by catheterization.

158 ry veins that were subsequently diagnosed by MRA.

159 catheterization were correctly diagnosed by MRA.

160 patients with suspected APVs were studied by MRA after inconclusive assessment by catheterization, TE

161 ot reveal additional aneurysms undetected by MRA.

162 ic resonance imaging/MRA, including cervical MRA at the last assessment.

163 to diagnostic catheterization and to compare MRA and x-ray angiography measurements of pulmonary arte

164 most active in the phyllosilicate-containing MRA.

165 Coronary MRA demonstrated a 23% increase in cross-sectional area

166 Coronary MRA may provide an alternative noninvasive method to dir

167 Free-breathing 3D coronary MRA accurately defines CAA in patients with Kawasaki dis

168 Free-breathing, T2prep, 3D coronary MRA with a shorter acquisition window resulted in improv

169 ng navigator-gated and corrected 3D coronary MRA.

170 blique submillimeter free-breathing coronary MRA allows depiction of extensive parts of the native co

171 Comparing coronary MRA and X-ray angiography, a good agreement of anatomy a

172 Nitroglycerin-enhanced coronary MRA can noninvasively measure coronary artery vasodilati

173 f 75 days (range, 1 to 359 days) of coronary MRA.

174 High-resolution multi-slice spiral coronary MRA (in-plane resolution of 0.52 to 0.75 mm) was perform

175 CAA from Kawasaki disease underwent coronary MRA using a free-breathing T2-prepared 3D bright blood s

176 ospective multicenter studies where coronary MRA is compared with X-ray angiography.

177 sured after exposing them to three different MRA substrates using either NaCl or NaClO(4) as a hygros

178 udy sought to assess the benefit of an early MRA regimen in acute MI irrespective of the presence of

179 he study failed to show the benefit of early MRA use in addition to standard therapy in patients admi

180 st, three-dimensional, spoiled gradient-echo MRA with surgical findings in 15 living renal donors.

181 Eight MRA studies were obtained in the three patients with sym

182 and basilar stenosis using contrast-enhanced MRA in consecutive patients, irrespective of age, presen

183 MRI with three-dimensional contrast-enhanced MRA provides rapid and comprehensive anatomic definition

184 dentified who underwent ferumoxytol-enhanced MRA after a nondiagnostic ultrasound for kidney dysfunct

185 Our study suggests that ferumoxytol-enhanced MRA may be a novel, safe method to accurately detect gra

186 We have found the gadolinium-enhanced MRA technique to be 100% accurate and as reliable as con

187 This study represents the first MRA analysis of a spontaneous preclinical brain tumor mo

188 -resolution three-dimensional time-of-flight MRA sequences at 3 T.

189 On time-of-flight MRA, the most common findings include loss of flow void

190 tion initiation or dose increase were 6% for MRA, 10% for beta-blocker, 7% for ACEI/ARB, and 10% for

191 In addition, average patient charge for MRA was compared with that of conventional angiogram.

192 ce of a critical and descriminating role for MRA.

193 Using a five-level grading system for MRA image quality (1 = nondiagnostic; 5 = excellent), th

194 Furthermore, MRAs attenuate the appearance of secondary hyperparathyr

195 The combined approach of 3D-Gd-MRA and PC-flow revealed the best (P = 0.0003) interobse

196 3D-Gd-MRA revealed a slightly improved interobserver variabili

197 ery ostium was significantly better in 3D-Gd-MRA than in DSA, whereas the visibility of the hilar and

198 y (DSA), 3D-Gadolinium MR angiography (3D-Gd-MRA), cine phase-contrast flow measurement (PC-flow), an

199 Cohort A: 31 patients had MRA, DSC-PWI and BOLD data.

200 Modifications engineered to reduce haploid MRA escape reduced false negative results in SGA-type an

201 actly half as many eyes were abnormal by HRT MRA.

202 severe glaucoma, sensitivity increased: HRT MRA, HRT GPS, and OCT would miss 5% of eyes, and GDx wou

203 The HRT MRA had the highest sensitivity (87.0%; 95% confidence i

204 When the HRT MRA was used as the diagnostic standard, sensitivities o

205 e and retention by the F98 rat glioma, human MRA melanoma, and murine L929 cell lines, all of which a

206 longitudinally by magnetic resonance imaging/MRA, including cervical MRA at the last assessment.

207 ssure-induced myogenic tone was increased in MRA and coronary artery from diabetic mice and normalize

208 art failure as of July 1, 2011, and incident MRA use between May 1 and September 30, 2011.

209 increased MRW (+6.04mum, p=.001), increased MRA (+0.014mm(2), p=.024), increased angle above referen

210 ith a 4-fold higher likelihood of initiating MRA therapy (HR, 4.10 [CI, 3.68 to 4.55]) and with bette

211 Isolated MRAs were mounted in an arteriograph and stimulated by 2

212 tly lower than those in the 0.1- and 1-mg/kg MRA and the placebo cohorts (6.4, 6.2, and 7.0, respecti

213 es fell significantly in the 5- and 10-mg/kg MRA cohorts and normalized 2 weeks after treatment.

214 ients in the placebo, 0.1-, 1-, and 10-mg/kg MRA cohorts).

215 s in the placebo, 0.1-, 1-, 5-, and 10-mg/kg MRA cohorts, respectively) required corticosteroid or di

216 ve interval between the initial and the last MRA was 306 months (mean, 30.6; range, 14 to 51 months).

217 tive interval between the first and the last MRA was 95 months (mean, 31.7; range, 15 to 49 months).

218 Mean MRA index of number and severity of stenoses was 0.84 +/

219 ge cultures from human metastatic melanomas (MRA cells) results in increased apoptosis and decreased

220 e deleterious mutations in this microregion (MRA) of UGT1A1 in CN-I patients are evidence of a critic

221 While need for receptor antagonist (MRA) MRA after diagnosis suggests that a defined daily dose (

222 magnetic resonance imaging/angiography (MRI/MRA) findings into large-vessel (LV) versus small-vessel

223 ed and manual approach was used to label MRI/MRAs with arteries, veins, brain parenchyma, cerebral sp

224 MRW, MRA, angle above the reference plane for MRW and MRA, BM

225 may decrease mortality for patients needing MRA.

226 at least 1 year of transfusions, and have no MRA-defined severe vasculopathy, hydroxycarbamide treatm

227 resonance angiography (MRA), and noncontrast MRA are each of limited use because of technical factors

228 s compared with 5 of 40 patients with normal MRA findings (P=.03).

229 enosis compared with 28 patients with normal MRA findings or mild stenosis (276.7 +/- 34 vs 215 +/- 1

230 A novel MRA vasculopathy grading scale demonstrated frequent sev

231 evaluate the diagnostic value of this novel MRA procedure to detect SLAP lesions in comparison to th

232 h catheterization and surgical observations, MRA had a 100% sensitivity and specificity for the diagn

233 in subacute stroke patients who had obvious MRA lesions with sparse collaterals, those with abundant

234 The remaining 16 patients without obvious MRA lesions showed neither TTP nor TSA time delay.

235 Spironolactone accounted for 99.4% of MRA use.

236 esponse to shear stress and acetylcholine of MRA and coronary artery from diabetic mice was altered a

237 Quantitative analysis of MRA images of spontaneous preclinical tumor models has n

238 suggests that a defined daily dose (DDD) of MRA between 12.5 and 50 mg may alleviate risk of death i

239 cidental ICA, and the rate of development of MRA-defined de novo ICA in these patients.

240 nt and prescription of appropriate dosage of MRA for PA patients.

241 (2%) patients were receiving target doses of MRA, beta-blocker, ACEI/ARB, and ARNI therapy, respectiv

242 pathophysiologic basis for the inclusion of MRA in the overall management of these disorders and the

243 fference was observed between the 5 mg/kg of MRA and placebo, with 5 patients (55.6%) in the MRA coho

244 ous dose of either 0.1, 1, 5, or 10 mg/kg of MRA or placebo.

245 n those who received 5 mg/kg and 10 mg/kg of MRA was 4.8 and 4.7 (P < 0.001 and P < 0.001 by analysis

246 The modification of MRA provides the requirements as a practicable routine s

247 d smooth muscle cell EGFR phosphorylation of MRA and coronary artery from diabetic mouse, which was r

248 This automated algorithm for processing of MRA images isolates and automatically identifies key fea

249 essel count, and the average vessel radii of MRA-visible vessels within the tumor.

250 the most appropriate therapeutic regimen of MRA in RA.

251 Although the spatial resolution of MRA is less than histologic analysis, MRA-obtained vascu

252 Although the spatial resolution of MRA prohibits visualization of capillaries, a high densi

253 ar intracranial aneurysms (ICA), the risk of MRA-defined growth of asymptomatic incidental ICA, and t

254 Median age at time of MRA initiation was 73 years, and 37.1% were women.

255 mprovement efforts that encourage the use of MRA should also include mechanisms to address recommende

256 mparative studies evaluating the efficacy of MRAs against other treatment arms for cCSCR.

257 is meta-analysis was to assess the impact of MRAs on SCD in patients with left ventricular systolic d

258 Comparative effectiveness studies of MRAs on SCD in usual care as well as studies evaluating

259 risk of hyperkalemia associated with use of MRAs for patients with HFrEF is reduced by sacubitril/va

260 morbidity and mortality; however, the use of MRAs in combination with other inhibitors of the renin-a

261 Use of MRAs was encouraged but left to the discretion of study

262 Patients initiated on MRA therapy as an outpatient had extremely poor rates of

263 fraction who were subsequently initiated on MRA therapy.

264 to prevent SCD in patients receiving optimal MRA therapy are needed to guide clinical decision-making

265 We are concerned that CTA or MRA may overlook mild cases of DSA-detectable FMD.

266 R package to infer gene networks and perform MRA from gene expression data, with optional corrections

267 ic resonance angiography (MRA), quantitative MRA, and high-resolution MRI of the atherosclerotic plaq

268 nd its attendant risks in patients receiving MRAs.

269 This work identified factors that reduce MRA escape, including insertion of terminator and repres

270 Standard MRA criteria were used to identify arterial tortuousity

271 In 13 of 16 subjects, MRA demonstrated normal graft vasculature, and an altern

272 In 2 of 16 subjects, MRA detected moderate to severe anastomotic stenoses, wh

273 In 1 of 16 subjects, MRA with ferumoxytol demonstrated complete arterial occl

274 including patients who newly started taking MRAs during the PARADIGM-HF trial, severe hyperkalemia r

275 ecificities and lower likelihood ratios than MRA.

276 These results indicate that MRA is an appropriate technique to follow small asymptom

277 The MRA compares measured rim area with predicted rim area a

278 The MRA measurements had low interobserver variability (< or

279 The MRA was evaluated at baseline (Heidelberg Retina Tomogra

280 est boron uptake was seen with N7-2OH by the MRA 27 melanoma and L929 wild-type (wt) cell lines.

281 All eyes classified as "borderline" by the MRA were assigned to the normal category (i.e., "within

282 and placebo, with 5 patients (55.6%) in the MRA cohort and none in the placebo cohort achieving ACR

283 erior and temporal-superior positions of the MRA are highly predictive for the onset of visual field

284 ator and repressor sequences upstream of the MRA cassette, deletion of silent mating-type loci, and u

285 sensitivity and specificity (95% CI) of the MRA result were 66.7% (58.0%-76.1%) and 88.7% (78.5%-94.

286 HR (for onset of visual field losses) of the MRA temporal-inferior sector outside normal limits was 3

287 accessory renal artery was suggested on the MRA but was not detected by conventional angiography.

288 ostic data available for comparison with the MRA findings.

289 Thirty MRA studies were obtained in 10 of the 15 patients with

290 tory results and adverse events proximate to MRA initiation.

291 n fraction of </=45%, randomized subjects to MRAs versus control and reported outcomes on SCD, total

292 stitutional experience with renal transplant MRA using ferumoxytol (a nonnephrotoxic medication) as a

293 utilization of alpha-type instead of a-type MRA.

294 d patients during this same period underwent MRA.

295 ion attenuates the risk of hyperkalemia when MRAs are combined with other inhibitors of the renin-ang

296 useful for confirming a normal disc, whereas MRA may be most helpful in confirming a suspicion of gla

297 e mitral valves of MVP patients treated with MRA.

298 Patients treated with MRAs had 23% lower odds of experiencing SCD compared wit

299 igher rates of evidence-based treatment with MRAs and better longitudinal BP control.

300 ed analysis demonstrated that treatment with MRAs was independently associated with a reduced risk of